Back to results
US 2017/0360723 A1Published application
Use of rasagiline for the treatment of restless legs syndrome
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsEran Blaugrund, Ruth Levy
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
Claims19
(canceled)
A pharmaceutical composition comprising in unit dosage form an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and an amount of pramipexole, wherein the amount of R(+)-N-propargyl-1-aminoindan or of the pharmaceutically acceptable salt thereof is from 0.5 mg to 1.66 mg and wherein the amount of pramipexole is from 0.125 mg to 0.6 mg.
Dependencies are inferred from the claim text.